Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 123, Issue 3, 2015, Pages 473-481

  Ung, Nolan ^a   Yang, Isaac ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

GBM; Glioblastoma multiforme; Immunotherapy; Nanoparticle; Nanotechnology

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CARBON NANOPARTICLE; CYANOACRYLATE DERIVATIVE; DENDRIMER; DOCETAXEL; DOXORUBICIN; IMMUNOMODULATING AGENT; IRON OXIDE NANOPARTICLE; LIPID NANOPARTICLE; LUTETIUM 177; NANOPARTICLE; POLY (PROPYLENEIMINE); POLYAMIDOAMINE; POLYBUTYL CYANOACRYLATE; POLYETHYLENEIMINE; POLYGLACTIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RIBONUCLEOPROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VAULT NANOPARTICLE;

BRACHYTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CYTOTOXICITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG RESPONSE; DRUG TARGETING; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE THERAPY; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR MICROENVIRONMENT; BRAIN NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; NANOTECHNOLOGY;

EID: 84937516532     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1814-1     Document Type: Review

References (75)

1. Ohgaki H et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899
2. Preusser M et al (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9–21
3. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
4. Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729
5. Patel MA, Kim JE, Ruzevick J, Li G, Lim M (2014) The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) 6:1953–1985
6. Nduom EK, Bouras A, Kaluzova M, Hadjipanayis CG (2012) Nanotechnology applications for glioblastoma. Neurosurg Clin N Am 23:439–449
7. Faraji AH, Wipf P (2009) Nanoparticles in cellular drug delivery. Bioorg Med Chem 17:2950–2962
8. Wohlfart S, Gelperina S, Kreuter J (2012) Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 161:264–273
9. Hernandez-Pedro NY et al (2013) Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int 2013:351031
10. Wang X et al (2014) Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review. Cancer Invest 32(9):451–457
11. Everson RG et al (2014) Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2:10
12. Kim W, Liau LM (2010) Dendritic cell vaccines for brain tumors. Neurosurg Clin N Am 21:139–157
13. Thaci B et al (2014) Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol 16:1304–1312
14. Choy W et al (2012) CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Neurosurg Clin N Am 23:391–405
15. Ooi YC et al (2014) The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg 119:125–132
16. Choi JY et al (2009) In vitro cytotoxicity screening of water-dispersible metal oxide nanoparticles in human cell lines. Bioprocess Biosyst Eng 33:21–30
17. Shokeen M et al (2011) Evaluation of multivalent, functional polymeric nanoparticles for imaging applications. ACS Nano 5:738–747
18. Chen K et al (2009) Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials 30:6912–6919
19. Ding H et al (2011) Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology 22:165101
20. Hong H et al (2011) Cancer-targeted optical imaging with fluorescent zinc oxide nanowires. Nano Lett 11:3744–3750
21. Schottelius M, Laufer B, Kessler H, Wester HJ (2009) Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 42:969–980
22. Gelperina S et al (2010) Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 74:157–163
23. Tahara K, Kato Y, Yamamoto H, Kreuter J, Kawashima Y (2011) Intracellular drug delivery using polysorbate 80-modified poly(d, l-lactide-co-glycolide) nanospheres to glioblastoma cells. J Microencapsul 28:29–36
24. Sawyer AJ et al (2011) Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res 1:34–42
25. Petri B et al (2007) Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Controll Release 117:51–58
26. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29–45
27. Kreuter J et al (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20:409–416
28. Ambruosi A et al (2006) Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target 14:97–105
29. Ambruosi A et al (2006) Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul 23:582–592
30. Steiniger SCJ et al (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759–767
31. Jachimczak P et al (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78:944–951
32. Jachimczak P et al (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65:332–337
33. Schneider T et al (2008) Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195:21–27
34. Li J et al (2011) The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma. Nanotechnology 22:435101
35. Sheng X et al (2012) Immunohistochemical localization of inhibin/activin subunits in the wild ground squirrel (citellus dauricus brandt) ovary. J Reprod Develop 58:531–536
36. Zhan C et al (2012) Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J Controll Release 160:630–636
37. Ofek P, Fischer W, Calderon M, Haag R, Satchi-Fainaro R (2010) In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J 24:3122–3134
38. Koppu S et al (2010) Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Controlled Release 143:215–221
39. Gajbhiye V, Jain NK (2011) The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 32(26):6213–6225
40. Agrawal A et al (2009) Functional delivery of siRNA in mice using dendriworms. ACS Nano 3:2495–2504
41. McNerny DQ et al (2009) RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. Bioconjug Chem 20:1853–1859
42. Ren Y et al (2010) Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 21:303–314
43. Han L et al (2010) Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 21:417–426
44. Lu Y-J, Wei K-C, Ma C-CM, Yang S-Y, Chen J-P (2012) Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B 89:1–9
45. Bobo RH et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076–2080
46. Hadjipanayis CG et al (2010) EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 70:6303–6312
47. Shultz MD et al (2011) Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model. Radiology 261:136–143
48. Bulte JW (2011) Science to practice: can theranostic fullerenes be used to treat brain tumors? Radiology 261:1–2
49. Shultz MD et al (2010) Encapsulation of a radiolabeled cluster inside a fullerene cage, (177)Lu(x)Lu((3-x))N@C(80): an interleukin-13-conjugated radiolabeled metallofullerene platform. J Am Chem Soc 132:4980–4981
50. Kuo Y-C, Liang C-T (2011) Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 32:3340–3350
51. Kundu P, Mohanty C, Sahoo SK (2012) Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater 8:2670–2687
52. Verreault M et al (2011) Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer 11:124
53. Roger M et al (2012) Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm 423:63–68
54. Jin J et al (2011) In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconj Chem 22:2568–2572
55. Nikanjam M et al (2007) Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86–94
56. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM (2007) Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Controll Release 124:163–171
57. Garcion E et al (2006) A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol Cancer Ther 5:1710–1722
58. Pinzón-Daza ML et al (2012) The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases the in vitro drug delivery across blood-brain barrier cells. Br J Pharm 167(7):1431–1447
59. Kuo Y-C, Liang C-T (2011) Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf B 85:131–137
60. Agarwal A, Mackey MA, El-Sayed MA, Bellamkonda RV (2011) Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano 5:4919–4926
61. Wang X et al (2012) Cancer stem cell labeling using poly(l-lysine)-modified iron oxide nanoparticles. Biomaterials 33:3719–3732
62. Dilnawaz F et al (2012) The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials 33:2936–2951
63. Lee HY et al (2008) PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 49:1371–1379
64. Zhang F et al (2012) Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 33:5414–5422
65. Gambarota G et al (2008) Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer 98:1784–1789
66. Plotkin M et al (2006) 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Int J Hyperth 22:319–325
67. van Landeghem FKH et al (2009) Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 30:52–57
68. Jordan A et al (2005) The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 78:7–14
69. Veiseh O et al (2010) Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 31:8032–8042
70. Buehler DC et al (2014) Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano 8:7723–7732
71. Rome LH, Kickhoefer VA (2013) Development of the vault particle as a platform technology. ACS Nano 7:889–902
72. Matsumoto NM, Prabhakaran P, Rome LH, Maynard HD (2013) Smart vaults: thermally-responsive protein nanocapsules. ACS Nano 7:867–874
73. Kickhoefer VA et al (2009) Targeting vault nanoparticles to specific cell surface receptors. ACS Nano 3:27–36
74. Kar UK et al (2011) Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One 6:e18758
75. Yang J et al (2012) Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies. Neurosurg Clin N Am 23:451–458